eFT 508

Drug Profile

eFT 508

Alternative Names: eFT-508

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Effector Therapeutics
  • Developer Effector Therapeutics; Merck AG; Pfizer
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Lymphoma; Solid tumours
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 01 Sep 2017 Phase-II clinical trials in Colorectal cancer (Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03258398)
  • 01 Sep 2017 Phase-II clinical trials in Colorectal cancer (Refractory metastatic disease, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT03258398)
  • 20 Jun 2017 eFFECTOR Therapeutics plans a phase II trial for Colorectal cancer (Second-line therapy or greater, Monotherapy, Combination therapy) in the third quarter of 2017 (PO) (NCT03258398)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top